Cocrystal Pharma Reports 2025 Financial Results

Biotech firm provides updates on antiviral drug development programs

Mar. 31, 2026 at 1:35pm

Got story updates? Submit your updates here. ›

A minimalist studio still life featuring a collection of laboratory equipment arranged in a clean, elegant composition, symbolizing the precision and innovation of pharmaceutical research.Cocrystal Pharma's financial report highlights continued investment in its pipeline of novel antiviral treatments.Bothell Today

Cocrystal Pharma, a Nasdaq-listed pharmaceutical company based in Bothell, Washington, has reported its 2025 financial results and provided updates on the progress of its antiviral drug development programs.

Why it matters

As a small biotech firm focused on developing novel antiviral treatments, Cocrystal Pharma's financial performance and pipeline updates are closely watched by investors and the broader pharmaceutical industry, especially in the wake of the COVID-19 pandemic.

The details

In its 2025 financial report, Cocrystal Pharma highlighted continued investment in its pipeline of antiviral drug candidates, including compounds targeting influenza, coronavirus, and norovirus. The company reported a net loss for the year but noted progress in advancing several drug candidates through clinical trials.

  • Cocrystal Pharma reported its 2025 financial results on March 31, 2026.

The players

Cocrystal Pharma, Inc.

A Nasdaq-listed pharmaceutical company focused on developing novel antiviral treatments.

Got photos? Submit your photos here. ›

What’s next

Cocrystal Pharma plans to provide further updates on its drug development programs and anticipated milestones in the coming months.

The takeaway

As the pharmaceutical industry continues to prioritize antiviral research, Cocrystal Pharma's financial performance and pipeline progress will be closely watched as it seeks to advance its portfolio of novel treatments.